Skip to main content
OpenTrials
Completed

NCT Number: NCT03479138

Non-Eosinophilic Neutrophilic Asthma

Define and characterize the neutrophilic phenotype of severe asthma.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Loading trial locations.

About this study

Neutrophilic asthma (NA) is the asthma phenotype less known, causes a severe disease and does not have a specific treatment. Research on the neutrophilia mechanisms, new neutrophil (NEU) types and bronchial microbiome, can provide an opportunity to better understand the NA pathogenesis.

OBJECTIVES: 1. To describe the clinical characteristics of NA and its sub-phenotypes (SUBSTUDY 1); 2. To determine the NEU types associated with the NA and its sub-phenotypes (SUBSTUDY 2); and 3. To identify the bronchial microbiological flora of the NA, specifically related to lung microbiome and the immune response against Chlamydia Pneumoniae (SUBSTUDY 3).

METHODS: Multicenter prospective study including 100 patients with severe asthma (GINA/GEMA criteria): 50 with non-neutrophilic asthma (<65% NEU in induced sputum [IS]); and 50 with NA (> 64% NEU in IS). SUBSTUDY 1: clinical variables (years of evolution, exacerbations, asthma control test, mini asthma quality of life questionnary), comorbidities (GERD, nasal polyposis, obesity, ASS), pulmonary function (FEV1, exhaled fraction of nitric oxide, total lung capacity, Aspergillus), prick-test and CT scan chest; SUBSTUDY 2 (in IS and plasma): apoptotic index by means NE culture and flux cytometer (Annexin-V-FITC), NEU phenotype by surface markers (CD16, CD66b, CD62L, HLADR, CD177, CD11b, CD63, CXCR2, CXCR4) with density gradient study and determination of cytokines (IL-6, IL-8, IL-17, IL-1, IL-22) by ELISA; SUBSTUDY 3 (in IS): bronchial microbiome for 16 subunit rRNA by Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt), and anti-Chlamydia Pneumoniae Immunoglobuling A by ELISA.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 - 80 years old
  • Confirmed diagnosis of asthma (according to spanish guideline GEMA)
  • Severe persistent asthma (step 5-6 GEMA)
  • Eosinophils<300/mm3 in peripheral blood

Exclusion criteria

  • Respiratory infection during the previous month
  • Significant lung pathology not attributable to asthma (bronchiectasis with Reiff score>3)

Treatment and study plan

Induced sputum

Diagnostic Test

Characterization with flow cytometry of the phenotype of the neutrophils isolated in the sputum, microbiome

Primary outcomes

  1. Phenotype of neutrophils

    Time frame: 24 hours

    To determine the types of neutrophils (in induced sputum and blood) associated with neutrophilic asthma and its subphenotypes according to flow cytometry

  2. Microbiome analysis

    Time frame: 6 months

    To analyse the bronchial microbiological flora of neutrophilic asthma

Secondary outcomes

  1. Clinical demographic characteristics

    Time frame: 1 year

    To describe the clinical characteristics and natural history of the neutrophilic asthma and its subphenotypes

  2. Demographic characteristics

    Time frame: 1 year

    To describe demographic characteristics

Sponsors and collaborators

Lead sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Other

Collaborators

  • Spanish Clinical Research Network - SCReN

Registry information

Acronym: ANNE

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Mar 27, 2018
Registry last updated
Jan 11, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.